EP3684336A4 - Méthodes et compositions pour le traitement d'une épidermolyse bulleuse - Google Patents

Méthodes et compositions pour le traitement d'une épidermolyse bulleuse Download PDF

Info

Publication number
EP3684336A4
EP3684336A4 EP18859166.3A EP18859166A EP3684336A4 EP 3684336 A4 EP3684336 A4 EP 3684336A4 EP 18859166 A EP18859166 A EP 18859166A EP 3684336 A4 EP3684336 A4 EP 3684336A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
epidermolysis bullosa
bullosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859166.3A
Other languages
German (de)
English (en)
Other versions
EP3684336A1 (fr
Inventor
Evangelos V. BADIAVAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US12558316B2/en
Application filed by University of Miami filed Critical University of Miami
Publication of EP3684336A1 publication Critical patent/EP3684336A1/fr
Publication of EP3684336A4 publication Critical patent/EP3684336A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Medicinal Preparation (AREA)
EP18859166.3A 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse Pending EP3684336A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US12558316B2 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Publications (2)

Publication Number Publication Date
EP3684336A1 EP3684336A1 (fr) 2020-07-29
EP3684336A4 true EP3684336A4 (fr) 2021-06-02

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859166.3A Pending EP3684336A4 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Country Status (10)

Country Link
EP (1) EP3684336A4 (fr)
JP (1) JP7525396B2 (fr)
KR (1) KR102722950B1 (fr)
CN (1) CN111182890A (fr)
AU (1) AU2018335788B2 (fr)
CA (1) CA3076610A1 (fr)
EA (1) EA202090814A1 (fr)
IL (1) IL273407B2 (fr)
MX (2) MX2020002777A (fr)
WO (1) WO2019060719A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
WO2014159662A1 (fr) 2013-03-13 2014-10-02 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
IL322149A (en) * 2019-05-03 2025-09-01 Cellphire Inc Materials and methods for manufacturing blood products
KR102125567B1 (ko) 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
AU2021327376A1 (en) * 2020-08-21 2023-04-20 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP3971440B1 (fr) 2020-09-21 2023-12-27 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
CA3217654A1 (fr) * 2021-04-23 2022-10-27 Spot Biosystems Ltd. Vesicules extracellulaires chargees de biomolecules
JP2024531238A (ja) * 2021-08-12 2024-08-29 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
US12589120B2 (en) 2021-10-12 2026-03-31 Eliksa Therapeutics, Inc. Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions
EP4694903A1 (fr) * 2023-04-11 2026-02-18 Eliksa Therapeutics, Inc. Procédés d'augmentation des niveaux de protéine thérapeutique et/ou d'amélioration de la fonction cellulaire avec des compositions de liquide amniotique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159662A1 (fr) * 2013-03-13 2014-10-02 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
WO2015038075A1 (fr) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Procédé
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
EP3402489B1 (fr) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
US20190133922A1 (en) * 2016-01-12 2019-05-09 Kangstem Biotech Co., Ltd. Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINH HA ET AL: "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges", ACTA PHARMACEUTICA SINICA B, vol. 6, no. 4, 1 July 2016 (2016-07-01), pages 287 - 296, XP055303644, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2016.02.001 *
See also references of WO2019060719A1 *

Also Published As

Publication number Publication date
AU2018335788B2 (en) 2024-08-15
CA3076610A1 (fr) 2019-03-28
IL273407B2 (en) 2025-09-01
IL273407A (en) 2020-05-31
MX2020002777A (es) 2020-09-17
JP2020534344A (ja) 2020-11-26
MX2022015753A (es) 2023-01-19
KR102722950B1 (ko) 2024-10-28
CN111182890A (zh) 2020-05-19
AU2018335788A1 (en) 2020-03-19
JP7525396B2 (ja) 2024-07-30
IL273407B1 (en) 2025-05-01
WO2019060719A1 (fr) 2019-03-28
EA202090814A1 (ru) 2020-08-07
KR20200088799A (ko) 2020-07-23
EP3684336A1 (fr) 2020-07-29

Similar Documents

Publication Publication Date Title
EP3684336A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3802553A4 (fr) Compositions contenant du silicium et procédés d'utilisation associés
EP3217795A4 (fr) Compositions et procédés de traitement avec des promédicaments du tizoxanide, un analogue ou un sel de celui-ci
EP3720421A4 (fr) Compositions et méthodes pour le traitement d'affections métaboliques
PL3448421T3 (pl) Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
EP3310783A4 (fr) Procédés et compositions de prévention et de traitement de la perte d'audition
SG11201912683QA (en) Treatment agent for epidermolysis bullosa
EP3185872A4 (fr) Formulations de testostérone et méthodes de traitement associées
EP3226873A4 (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3185910A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3423064A4 (fr) Formulations de testostérone et méthodes de traitement associées
EP3349719A4 (fr) Compositions et méthodes destinées au traitement et à la prévention de la dermatite de rayonnement
EP3271320A4 (fr) Compositions pour le traitement de la fibrose et d'états associés à la fibrose
HK40031789A (en) Methods and compositions for the treatment of epidermolysis bullosa
HK40038038A (en) Methods of treatment of hypertrigl yceridemia
HK40036545A (en) Compositions and methods for treatment of fibrosis
HK40029034A (en) Methods and compositions for the treatment of cancer
HK40024990A (en) Methods and compositions for the treatment of cancer cachexia
HK40040215A (en) Methods of treating phenylketonuria
AU2017904906A0 (en) Methods of treatment
HK40032647A (en) Compositions and methods for treatment of atopic dermatitis and treatment selection
HK40015941A (en) Compositions and methods for the treatment of hemoglobinopathies
HK40036149A (en) Cas12c compositions and methods of use
HK40036150A (en) Casz compositions and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031789

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20210429BHEP

Ipc: A61K 35/28 20150101ALI20210429BHEP

Ipc: A61Q 19/00 20060101ALI20210429BHEP

Ipc: A61P 17/00 20060101ALI20210429BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240830